Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
    • Overview
    • Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • Analyst Coverage
    • Events
    • SEC Filings
    • FAQs
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
    ►
      ◄ Back
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • FAQs
  • Get in Touch
  • Join Us

Investors & Media

Press Releases

All News | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

May 12, 2022

TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 02, 2022

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 01, 2022

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 22, 2022

TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update

Mar 08, 2022

TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022

Mar 04, 2022

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 09, 2022

TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference

Jan 12, 2022

TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

Jan 10, 2022

TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones

Jan 07, 2022

TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • Contact IR
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
  • Get in Touch
  • Join Us

© 2022 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics